IDACORP (IDA) Announces $450M Share Offering

IDACORP, Inc. (NYSE: IDA) announced today that it has commenced an underwritten public offering of $450 million of shares of its common stock. Subject to certain conditions, all shares are expected to be borrowed by the forward sellers, Morgan Stanley, J.P. Morgan, and Wells Fargo Securities (or their respective affiliates), from third parties and sold to the underwriters in the offering in connection with the forward sale agreements described below. In conjunction with the offering, IDACORP intends to grant to the underwriters an option to purchase up to $67.5 million of additional shares of its common stock. If such option is exercised, IDACORP may, in its sole discretion, enter into additional forward sale agreements with the forward purchasers (or their respective affiliates) with respect to such additional shares.

Morgan Stanley, J.P. Morgan, and Wells Fargo Securities are acting as joint lead bookrunners of the offering and representatives for the underwriters. BofA Securities, Mizuho, and MUFG are also acting as bookrunners for the offering. The underwriters may offer the shares of common stock in transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.

In connection with the offering, IDACORP intends to enter into separate forward sale agreements with each of Morgan Stanley & Co. LLC, JPMorgan Chase Bank, National Association, New York Branch, and Wells Fargo Bank, National Association, referred to in such capacity as the forward purchasers, pursuant to which IDACORP will agree to sell to the forward purchasers or their respective affiliates approximately $450 million of shares of common stock at an initial forward sale price per share equal to the price per share at which the underwriters purchase the shares in the offering, subject to certain adjustments, upon physical settlement of the forward sale agreements. Settlement of the forward sale agreements is expected to occur no later than 18 months following the completion of the offering. IDACORP may, subject to certain conditions, elect cash settlement or net share settlement for all or a portion of its rights or obligations under the forward sale agreements.

IDACORP will not initially receive any proceeds from the sale of shares of its common stock by the forward sellers (or their respective affiliates) to the underwriters. If IDACORP elects physical settlement of the forward sale agreements, it expects to use any net proceeds for general corporate purposes, which may include capital expenditures.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make an offer, solicitation or sale in such jurisdiction. The public offering is being made pursuant to an effective shelf registration statement that has been filed with the Securities and Exchange Commission, or SEC. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. In addition, copies of the prospectus and preliminary prospectus supplement relating to the shares of common stock offered in the offering may be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; J.P. Morgan Securities LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] and [email protected]; or Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, at 800-645-3751 (option #5) or email a request to [email protected].

You May Also Be Interested In

• Select Medical stockholders approve buyout by insider-led consortium
• Securitize SPAC deal to raise $400M, NYSE listing set for July
• Decoy Therapeutics announces up to $21M private placement